The late-stage skin condition biotech Nolan is looking to batter ongoing headwinds and gun for a $60 million public offering.

The Durham, NC-based company, which is around a decade old, is working on nitric oxide based therapies for dermatologic indications, including acne.

According to its SEC-1 filing, the company plans to list on the Nasdaq under the symbol $NOVN.

Read the full article at